STAT+: Pharmalittle: Activist investor targets Cardinal Health; 340B drug sales rose to $44 billion last year
Top of the morning to you, and a fine one it is. Crystal clear blue…
Category: STAT+
STAT+: Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup
Among the most notable aspects of the Covid-19 vaccine race was who won it: Pfizer…
Opinion: STAT+: Clinical validation will save digital health’s reputation
The meteoric rise of telehealth and other types of virtual care during the Covid-19 pandemic…
STAT+: Unpacking the drug pricing policies that Congress just approved
WASHINGTON — Medicare coverage for prescription drugs will look very different when President Biden signs…
STAT+: Sales from controversial drug discount program rose to $44 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $44…
STAT+: Bright Health Group heads toward insolvency as it rushes to raise more cash
A little more than a year after going public, Bright Health Group is in danger…
.jpg)
STAT+: Pharmalittle: U.S. House passes drug-pricing legislation; U.K. is first country to approve a bivalent Covid shot
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
.jpg)
STAT+: Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections
Last year, the Food and Drug Administration issued a rare public statement to inform the…
STAT+: A treatment for monkeypox was approved under the FDA’s ‘Animal Rule.’ Here’s what that means
Take a look at the list of conditions that have treatments available thanks to what’s…
STAT+: The private equity firms, like Blackstone and KKR, behind 8 of the biggest names in autism therapy
Private equity investors are backing all of the major chains offering the country’s most popular…
STAT+: Pharmalittle: Two children died after getting Novartis gene therapy; monkeypox vaccine maker warns about splitting doses
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Wyden wants details on Amgen’s U.S. taxes as part of expanding probe into pharma practices
The head of the U.S. Senate Finance Committee is seeking details from Amgen about the…
STAT+: Novartis reports two children died from acute liver failure after treatment with Zolgensma gene therapy
Two children have died from acute liver failure after being administered Zolgensma, a pricey gene…
STAT+: One Medical’s dueling offers from Amazon and CVS signal a start to health tech bidding wars
It’s health tech hunting season for some of America’s biggest brand names. Over the last…
STAT+: Pharmalittle: Judge rules Walgreens helped fuel San Francisco opioid crisis; U.S. plan to bottle monkeypox vaccine could take months
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: The FDA’s ‘breakthrough’ medical devices are finally hitting the market in numbers
The Breakthrough Device Program is approaching terminal velocity. The Food and Drug Administration, looking to…
STAT+: Amid Aduhelm woes, Biogen moves to pare back office space
Biogen is moving to scale back its real estate footprint in Kendall Square and in Weston,…
STAT+: Pharmalittle: Endo bankruptcy filing over opioid crisis appears imminent; U.S. to allow fractional doses of monkeypox vaccine
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Everything you need to know before the next big Alzheimer’s readout
With the tumultuous rollout of Aduhelm behind them, partners Biogen and Eisai have the rare…
STAT+: Pharmalittle: Pfizer to test a Lyme disease vaccine; only monkeypox drug in the U.S. is hard to access
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT+: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally
The $5.4 billion acquisition of Global Blood Therapeutics by Pfizer was sealed with a phone…
STAT+: For the second time, Pfizer tries a drug warranty in response to concerns over high costs
For only the second time, Pfizer is offering a warranty for a medicine that will…
STAT+: The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences
There’s really no ignoring the inexorable math that led the Senate to approve a plan…
STAT+: Pharmalittle: Medicare is poised to negotiate drug prices; Pfizer to pay $5.4 billion for Global Blood Therapeutics
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach
Karuna Therapeutics said Monday that a novel combination pill reduced psychosis and related symptoms experienced…
STAT+: Telehealth fraud concerns, whether ‘overblown’ or not, could impact the industry’s future
Recent federal crackdowns on Medicare fraud linked to telehealth have raised concerns in Washington that…
STAT+: Health care industry swarms Washington as surprise billing rules get ironed out
Solving surprise medical bills was supposed to be straightforward. It has been anything but. Already,…
STAT+: At pioneering center for gene therapy, Jim Wilson presided over toxic, abusive workplace, staffers say
Scientist Jim Wilson is synonymous with gene therapy — and for good reason. For decades,…
STAT+: Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug
A clinical trial run by Amgen that combined its KRAS-targeting cancer drug called Lumakras with…
STAT+: Pharmalittle: PhRMA threatens Dems if drug-pricing bill passes; Novo plays down worries over obesity drug supplies
And so, another working week will soon draw to a close. Not a moment too…
STAT+: From buzzy biomarkers to learning from failure: 3 takeaways from the Alzheimer’s Association International Conference
SAN DIEGO — From exploring new ways to spot the disease to rethinking what Alzheimer’s…
STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot…
STAT+: Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder
Amgen said Thursday that it will acquire the small drugmaker ChemoCentryx for $4 billion to…
STAT+: ‘How can you not be excited?’: AI experts share enthusiasm about its future in health care
While the adoption of artificial intelligence in health care has been slow and bumpy at…
STAT+: Lilly is ordered to pay $61 million for shortchanging the Medicaid drug rebate program
After nearly a decade of legal squabbling, Eli Lilly was ordered by a federal court…
STAT+: Civica Rx begins selling its first generic drug as it tries to overhaul the pharmaceutical supply chain
In the latest bid to address high prescription drug costs, a nonprofit plans to sell…
STAT+: Pharmalittle: AbbVie wins court opinion on Humira patent thickets; Alnylam heart disease drug succeeds in closely watched trial
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Alnylam therapy for increasingly common heart disease succeeds in closely watched trial
Alnylam Pharmaceuticals’ treatment for an increasingly common heart disease succeeded in a closely watched clinical…
STAT+: U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition
In a significant victory for AbbVie, a U.S. appeals court panel declined to revive a…
STAT+: How much are patients actually using mental health apps? Research on engagement is elusive
As companies selling health care apps struggle to prove to a skeptical system that they…
STAT+: Pharmalittle: West Virginia cities reach deal with wholesalers over opioid crisis; Democrats’ economic plan would raises taxes on pharma
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Alexis Borisy, biotech’s ‘man of many hats,’ dons another
Alexis Borisy is the first person to admit he has a lot of projects going…
Opinion: STAT+: Hospitals, health systems play critical roles in the real-world data movement
Since the start of the pandemic, the health care and life sciences sectors have relied…
STAT+: Hospitals win higher payments from Medicare after lobbying campaign
Hospitals secured significantly larger payments from Medicare for 2023, after months of lobbying centered around…
STAT+: Major European research funders often fail to set policies or monitor progress on clinical trial transparency
Nearly two dozen major organizations that fund medical research in Europe often failed to set…
STAT+: Pharmalittle: Global demand for monkeypox vaccine will be hard to meet; Amgen dispute with IRS heats up
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: This billionaire has quietly driven Boston’s biotech industry for decades
Among the small bunch of billionaires that the local biotech industry has created, Tim Springer…
STAT+: Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy
Sarepta Therapeutics said Friday that it intends seek regulators’ approval for its gene therapy to…
STAT+: Pharmalittle: Pharma wages ‘hail Mary’ campaign to sink reconciliation bill; Moderna inks $1.74 billion deal with U.S. for Omicron shot
And so, another working week will soon draw to a close. Not a moment too…
STAT+: A ViiV deal to license its HIV prevention shot to poor countries runs into criticism
In a much ballyhooed move, ViiV Healthcare finalized a deal to license its long-acting injectable…